Sign up for our Free monthly newsletter
www.jashbotanicals.com \\ articles \ Natural Guide to Bone Joint & Arthritis
bone joint arthritis
Introductions The Heavy Metal Connection Physical Recommendations
Benefits of a Natural Approach Special Considerations Joint Replacement: An Innovative Approach
The Nutrition Connection Nutrient Recommendations Where to Get Help
The Allergy / Arthritis Connection Herbal Recommendations References
Printer friendly pdf for bone joint arthritis



References

  1. "Alternatives to NSAIDs for Osteoarthritis" by Dean Raffelock, in the November, 2001 issue of the John R. Lee, MD Medical Letter (pp5-6).
  2. Dr. Julian Whitaker's Health & Healing; Your Definitive Guide to Alternative Health and Anti-Aging Medicine, Vol. 12, No. 8 (Aug 02) "The Many Benefits of Plant Sterols," pp.1-3.
  3. Mediators of Inflammation, on the site of the Pathology Department of the University of Western Ontario in London, Ontario, Canada.
  4. Herbs in Rheumatology, by Jim Duke, PhD, on the site of Willner Pharmacy, "the oldest and largest nutritionally oriented Pharmacy in North America"
  5. Environmental Protection Agency. "EPA Data Show Steady Progress in Cleaning Nation's Air." Environmental News (Oct, 1992). As reported in "Did You Know" Our Toxic Times 3 no. 12 (Dec, 1992):5.
  6. Environmental Protection Agency. "130 Cities Exceed Lead Levels for Drinking Water." Environmental News (Oct, 1992). As reported in "Did You Know" Our Toxic Times 3 no. 12 (Dec, 1992):3.
  7. Saifer, P., M.D. Detox. Los Angeles: Jeremy P. Tarcher, Inc., 1984.
  8. Schnare, D. W. The Unpolluting of Man. Los Angeles: Foundation Essay Series Foundation for Advancements in Science and Education, n.d. Video.
  9. British Journal of Nutrition, November 2000, vol. 84, no. 5, pp. 589-595(1)
  10. The British Journal of Rheumatology, Vol 30, 125-134, Copyright © 1991 by British Society for Rheumatology
  11. Hafström I, Ringertz B, Spangberg A et al. A vegan diet free of gluten improves the signs and symptoms of rheumatoid arthritis: the effects on arthritis correlate with a reduction in antibodies to food antigens. Rheumatology2001;40:1175–9.[Abstract/Free Full Text]
  12. Kjeldsen-Kragh J, Haugen M, Borchgrevink CF et al. Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis. Lancet1991;338:899–902.[ISI][Medline]
  13. Peltonen R, Kjeldsen-Kragh J, Haugen M et al. Changes of Faecal flora in rheumatoid arthritis during fasting and one-year vegetarian diet. Br J Rheumatol1994;33:638–43.[ISI][Medline]
  14. Peltonen R, Nenonen M, Helve T, Hänninen O, Toivanen P, Eerola E. Faecal microbial flora and disease activity in rheumatoid arthritis during a vegan diet. Br J Rheumatol1997;36:64–8.[ISI][Medline]
  15. Eerola E, Möttönen T, Hannonen P et al. Intestinal flora in early rheumatoid arthritis. Br J Rheumatol1994;33:1030–8.[ISI][Medline]
  16. Simelyte E, Rimpiläinen M, Lehtonen L, Zhang X, Toivanen P. Bacterial cell wall-induced arthritis: chemical composition and tissue distribution of four Lactobacillus strains. Infect Immun2000;68:3535–40.[Abstract/Free Full Text]
  17. Toivanen P. From reactive arthritis to rheumatoid arthritis. J Autoimmun2001;16:369–71.[ISI][Medline]
  18. Zhang X, Rimpiläinen M, Simelyte E, Toivanen P. Enzyme degradation and proinflammatory activity in arthritogenic and nonarthritogenic Eubacterium aerofaciens cell walls. Infect Immun2001;69:7277–84.[Abstract/Free Full Text]
  19. Taurog JD, Richardson JA, Croft JT et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med1994;180:2359–64.[Abstract]
  20. Rehakova Z, Capkova J, Stepankova R et al. Germ-free mice do not develop ankylosizing enthesopathy, a spontaneous joint disease. Hum Im
  21. (Br Med J 96;312:570-572)
  22. Human Ecology and Susceptibility to the Chemical Environment (1962), An Alternative Approach to Allergies (1980, 1981, 1989), and Environmental Medicine – Beginnings and Bibliography of Clinical Ecology (1987).
  23. 1Randolph, T.G., "Ecologically Orientated Rheumatoid Arthritis" and "Ecologically Orientated Myalgia and Related Musculoskeletal Painful Syndromes" in Dickey, L.D., editor, Clinical Ecology, Thomas, 1976, pp. 201-223.
  24. 2Panush, R.S., R.M. Stroud, and E.M. Webster, Vol. 29, No.2 (February 1986), pp. 220-226.
  25. 3Darlington, L.G., N.W. Ramsey, and J.R. Mansfield, February 1, 1986, pp. 236-238.
  26. 4Panush, R.S. et.al., "Diet Therapy for Rheumatoid Arthritis," Arthritis and Rheumatism, Vol. 26, No. 4 (April 1983), pp. 462-471.
  27. Article from NOHA NEWS, Vol. XII, No. 3, Spring 1987, page 3.
  28. Casarett & Doull's Toxicology. Fifth Edition, 1996.
  29. World Resources Institute. "Heavy Metals and Health." Available on-line at http://www.wri.org/wri/wr-98-99/metals2.htm
  30. Occupational Safety and Health Administration (OSHA). "Heavy Metals" Available on-line at http://www.osha-slc.gov/SLTC/metalsheavy/index.html
  31. Resch KL, Hill S, Ernst E. Use of complementary therapies by individuals with `arthritis'. Clin Rheumatol 1997;16:391-5.
  32. Barclay TS, Tsourounis C, McCart GM. Glucosamine. Ann Pharmacother 1998;32:574-9.
  33. Setnikar I, Pacini MA, Revel L. Antiarthritic effects of glucosamine sulfate studied in animal models. Arzneimittelforschung 1991;41:542-5.
  34. Rindone JP, Hiller D, Collacott E, Nordhaugen N, Arriola G. Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med 2000;172:91-4.
  35. Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999;26:2423-30.
  36. Delafuente JC. Glucosamine in the treatment of osteoarthritis. Rheum Dis Clin North Am 2000;26: 1-11.
  37. Qiu GX, Gao SN, Giacovelli G, Rovati L, Setnikar I. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneimittelforschung 1998;48:469-74.
  38. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000;283:1469-75.
  39. Towheed TE, Anastassiades TP, Shea B, Houpt J, Welch V, Hochberg MC. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2001;1:CD002946.
  40. Lopes Vaz A. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Curr Med Res Opin 1982;8: 145-9.
  41. Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz JL, Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 3 400 mg/day vs placebo. Osteoarthritis Cartilage 1998;6(suppl A):25-30.
  42. Leeb BF, Schweitzer H, Montag K, Smolen JS. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205-11.
  43. Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996;23: 1385-91.
  44. Kelly GS. The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. Altern Med Rev 1998;3:27-39.
  45. Leffler CT, Philippi AF, Leffler SG, Mosure JC, Kim PD. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. Mil Med 1999;164: 85-91.
  46. McCarty MF. The neglect of glucosamine as a treatment for osteoarthritis-a personal perspective. Med Hypotheses 1994;42:323-7.
  47. The review of natural products. Drugs Facts and Comparisons. St. Louis, Mo.: Facts and Comparisons, 1996.
  48. Di Padova C. S-adenosylmethionine in the treatment of osteoarthritis. Review of the clinical studies. Am J Med 1987;83:60-5.
  49. Bradley JD, Flusser D, Katz BP, Schumacher HR Jr, Brandt KD, Chambers MA, et al. A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis. J Rheumatol 1994;21:905-11.
  50. Barcelo HA, Wiemeyer JC, Sagasta CL, Macias M, Barreira JC. Effect of S-adenosylmethionine on experimental osteoarthritis in rabbits. Am J Med 1987;83:55-9.
  51. Konig B. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med 1987;83:89-94.
  52. Srivastava KC, Mustafa T. Ginger (Zingiber officinale) in rheumatism and musculoskeletal disorders. Med Hypotheses 1992;39:342-8.
  53. Muller-Fassbender H. Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis. Am J Med 1987;83:81-3.
  54. Vetter G. Double-blind comparative clinical trial with S-adenosylmethionine and indomethacin in the treatment of osteoarthritis. Am J Med 1987; 83:78-80.
  55. (25). Maccagno A, Di Giorgio EE, Caston OL, Sagasta CL. Double-blind controlled clinical trial of oral S-adenosylmethionine versus piroxicam in knee osteoarthritis. Am J Med 1987;83:72-7.
  56. (26.) Caruso I, Pietrogrande V. Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease. Am J Med 1987;83:66-71.
  57. (27.) Glorioso S, Todesco S, Mazzi A, Marcolongo R, Giordano M, Colombo B, et al. Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis. Int J Clin Pharmacol Res 1985;5:39-49.
  58. (28.) Bliddal H, Rosetzsky A, Schlichting P, Weidner MS, Andersen LA, Ibfelt HH, et al. A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis Cartilage 2000;8:9-12.
  59. Beth M. Ley Jacobs, Ph.D., is author of MSM: On Our Way Back to Health With Sulfur (BL Publications, 1998).
  60. Oae S., Okuyama T. Organic sulfur chemistry: biochemical aspects. Boca Raton (FL): CRC Press; 1992. p.138-40.

  61. Rezvukhin AI, et al. Stabilization of omega-3-polyunsaturated acids in fat from Mallotus villosus (Osmeridae) by the nontoxic, sulfur-containing antioxidant CO- Vopr Med Khim 1995 May-Jun;41(3):37-9.

  62. Reichelt A, et al. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomized, placebo-controlled, double-blind study. Arzneimittelforschung 1994 Jan;44(1):75-80.

  63. Lawrence RM. Methylsulfonylmethane (MSM): a double-blind study of its use in degenerative arthritis. Int J of Anti-Aging Med 1998 July;1(1):50.

  64. Jacob SW, Herschler R. Biological actions and medical applications of dimethyl sulfoxide. Ann NY Acad Sci 1983;411:xiii-vii.
  65. Simopoulos, Artemis. Omega-3 fatty acids in health and disease and in growth and development. American Journal of Clinical Nutrition, Vol. 54, 1991, pp. 438-63
  66. Pepping, Joseph. Omega-3 essential fatty acids. American Journal of Health-System Pharmacy, Vol. 56, April 15, 1999, pp. 719-24
  67. Uauy-Dagach, Ricardo and Valenzuela, Alfonso. Marine oils: the health benefits of n-3 fatty acids. Nutrition Reviews, Vol. 54, November 1996, pp. S102-S108
  68. Connor, William E. Importance of n-3 fatty acids in health and disease. American Journal of Clinical Nutrition, Vol. 71 (suppl), January 2000, pp. 171S-75S
  69. DiGiacomo, Ralph A. , et al. Fish-oil Dietary Supplementation in Patients with Raynaud's Phenomenon: A Double-Blind, Controlled, Prospective Study. The American Journal of Medicine, Vol. 86, February 1989, pp. 158-164
  70. Levine, Barbara S. Most frequently asked questions about DHA. Nutrition Today, Vol. 32, November/December 1997, pp. 248-49
  71. Kalmijn, S., et al. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. American Journal of Epidemiology, Vol. 145, January 1, 1997, pp. 33-41
  72. Kalmijn, S., et al. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Annals of Neurology, Vol. 42(5), November 1997, pp. 776-82
  73. Yehuda, S., et al. Essential fatty acids preparation (SR-3) improves Alzheimer's patients quality of life. International Journal of Neuroscience, Vol. 87(3-4), November 1996, pp. 141-9
  74. Edwards, R., et al. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. Journal of Affective Disorders, Vol. 48, March 1998, pp. 149-55
  75. Hibbeln, Joseph R. Fish consumption and major depression. The Lancet, Vol. 351, April 18, 1998, p. 1213 (correspondence)
  76. Hibbeln, Joseph R. and Salem, Norman. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. American Journal of Clinical Nutrition, Vol. 62, July 1995, pp. 1-9
  77. Stoll, Andrew L., et al. Omega 3 fatty acids in bipolar disorder. Archives of General Psychiatry, Vol. 56, May 1999, pp. 407-12 and pp. 415-16 (commentary)
  78. Calabrese, Joseph R., et al. Fish oils and bipolar disorder. Archives of General Psychiatry, Vol. 56, May 1999, pp. 413-14 (commentary)
  79. Laugharne, J.D.E., et al. Fatty acids and schizophrenia. Lipids, Vol. 31 (suppl), 1996, pp. S163-S65 Jensen, Craig L., et al. Effect of docosahexaenoic acid supplementation of lactating women on the fatty acid composition of breast milk lipids and maternal and infant plasma phospholipids.

    American Journal of Clinical Nutrition, Vol. 71 (suppl), January 2000, pp. 292S-99S
  80. Makrides, Maria and Gibson, Robert A. Long-chain polyunsaturated fatty acid requirements during pregnancy and lactation. American Journal of Clinical Nutrition, Vol. 71 (suppl), 2000, pp. 307S-11S
  81. Connor, William E., et al. Increased docosahexaenoic acid levels in human newborn infants by administration of sardines and fish oil during pregnancy. Lipids, Vol. 31 (suppl), 1996, pp. S183-S87
  82. Cunnane, S.C., et al. Breast-fed infants achieve a higher rate of brain and whole body docosahexaenoate accumulation than formula-fed infants not consuming dietary docosahexaenoate. Lipids, Vol. 35, January 2000, pp. 105-11
  83. Carlson, S.E., et al. Long-chain polyunsaturated fatty acids and development of human infants. Acta Paediatr Suppl, Vol. 88 (430), August 1999, pp. 72-7
  84. Mitchell, E.A., et al. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin Pediatr (Phila), Vol. 26, August 1987, pp. 406-11
  85. Stevens, Laura J., et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. American Journal of Clinical Nutrition, Vol. 62, No. 4, October 1995, pp. 761-68
  86. Hodge, Linda, et al. Consumption of oily fish and childhood asthma risk. Medical Journal of Australia, Vol. 164, February 5, 1996, pp. 137-40
  87. Broughton, K. Shane, et al. Reduced asthma symptoms with n-3 fatty acid ingestion are related to 5-series leukotriene production. American Journal of Clinical Nutrition, Vol. 65, April 1997, pp. 1011-17
  88. Dry, J. and Vincent, D. Effect of a fish oil diet on asthma: results of a 1-year double-blind study. International Archives of Allergy and Applied Immunology, Vol. 95, No. 2/3, 1991, pp. 156-7
  89. Shahar, Eyal, et al. Dietary n-3 polyunsaturated fatty acids and smoking-related chronic obstructive pulmonary disease. The New England Journal of Medicine, Vol. 331, No. 4, July 28, 1994, pp. 228-33
  90. Gruenwald J, et al. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
  91. Bingham, R, et al, ‘Yucca plant saponin in the management of arthritis', Journal of Applied Nutrition, 27:45-50, 1975.
  92. Schulz V, Hansel R, Tyler VE. Rational Phytotherapy: A Physician's Guide to Herbal Medicine. Terry C. Telger, transl. 3rd ed. Berlin, GER: Springer, 1998.
  93. Botanical Influences on Illness, A sourcebook of Clinical Research, Melvyn R. Werbach, M.D., Assistant Clinical Professor, UCLA School of
  94. Medicine. 1994. Page 330.
  95. Dewidar AM, El-Munajjed D. The steroid sapogenin constituents of Agave americana, A. variegata and Yucca gloriosa. Planta Med 170; 19: 87–91.(PubMed)
  96. Backer RC et al. A phytochemical investigation of Yucca schotti (Liliaceae). J Pharm Sci 1972; 61: 1665–1666.(PubMed)
  97. Stohs SJ et al. Steroidal sapogenins of Yucca glauca seeds. Lloydia 1973; 36: 443.
  98. Ali MS et al. Isolation of antitumor polysaccharide fractions from Yucca glauca Nutt. (Liliaceae). Growth 1978; 42: 213–223.(PubMed)
  99. Bingham R et al. Yucca plant saponin in the management of arthritis. J Appl Nutr 1975; 27: 45–51.
  100. Bingham R et al. Yucca plant saponin in the treatment of hypertension and hypercholesterol emia. J Appl Nutr 1978; 30: 127–136.
  101. Planta Med 1979 Dec; 37(4) 367-9
  102. Planta Med 1993 Feb;59(1):12-6
  103. Arzneimittelforschung 1977 Jul;27(7):1455-7
  104. Altern Ther Health Med. 2003 May-Jun; 9(3):74-9
  105. J Assoc Physicians India 1994 Jun: 42(6) 454-5
  106. Planta Med 1984 Feb(1) 78-80
  107. Arzneimittelforschung 1977 Jul;27(7):1455-7
Site Map Legal Disclaimer Privacy Statement
Disclaimer: None of the above statements have been evaluated or approved by the Food and Drug Administration or the American Medical Association. The information provided on this site is intended for your general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider before using any herbal products.